Browse News
Filter News
Found 1,022 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
RNAi Therapeutics Market Size to Climb USD 4.28 Billion by 2033
4/17/2024
The RNAi therapeutics market size reached a value of USD 1.11 billion by 2023 is expected to surge USD 4.28 billion by 2033, projections indicate an impressive CAGR of 14.9% over the forecast period 2023 – 2033, a study by Towards Healthcare.
-
Biochip Market Size to Hit Around USD 40.49 Billion By 2033
4/17/2024
According to Nova One Advisor, the global biochip market size was estimated at USD 12.28 billion in 2023 and is projected to hit around USD 40.49 billion by 2033, growing at a CAGR of 12.67% during the forecast period from 2024 to 2033.
-
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
4/17/2024
G1 Therapeutics, Inc will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET.
-
Active Pharmaceutical Ingredients Market Size to Increase USD 416.15 Billion By 2033
4/15/2024
The global active pharmaceutical ingredients market size was evaluated at USD 237.48 billion in 2023 and it is expected to increase around USD 416.15 billion by 2033 with a CAGR of 5.77% from 2024 to 2033.
-
High-Performance Liquid Chromatography Market Worth $7.30 Bn by 2031
4/10/2024
Global High-Performance Liquid Chromatography Market is valued at US$ 5.16 Bn in 2023, and it is expected to reach US$ 7.30 Bn by 2031, with a CAGR of 4.43% during the forecast period of 2024-2031.
-
Cancer Immunotherapy Market Size to Increase USD 280.11 BN by 2033
4/8/2024
According to Vision Research Reports, the global cancer immunotherapy market size was estimated at USD 125.73 billion in 2023 and it is projected to increase USD 280.11 billion by 2033 with a CAGR of 8.34% from 2024 to 2033.
-
Cell And Gene Therapy Manufacturing Market is Rising Rapidly
4/4/2024
The global cell and gene therapy manufacturing market size was evaluated at USD 9.95 billion in 2023 and is expected to attain around USD 106.03 billion by 2033
-
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/4/2024
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET.
-
Opthea Appoints Sujal Shah to the Board of Directors
4/3/2024
Opthea Limited, a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, announced the appointment of Sujal Shah to the Company’s Board of Directors, effective April 4, 2024.
-
Single-cell Analysis Market Poised for Substantial Growth 18.33%
4/2/2024
The single-cell analysis market size was estimated at USD 4.64 billion in 2023 and it is increasing up to USD 24.97 billion by 2033
-
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
4/2/2024
Zentalis® Pharmaceuticals, Inc. will present a poster with new preclinical data at the 2024 Annual Meeting of the American Association for Cancer Research taking place in San Diego April 5-10, 2024.
-
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
4/2/2024
Upstream Bio, a clinical-stage biotech company advancing verekitug for respiratory disorders, announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.
-
Microbiology Testing Market Experiencing Rapid Growth
4/1/2024
The global microbiology testing market size was valued at USD 5.33 billion in 2023 and it is expected to surpass around USD 12.72 billion by 2033 with a CAGR of 9.12% from 2024 to 2033 due to the increasing demand for genetic testing services.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024
4/1/2024
G1 Therapeutics, Inc. announced the grant of inducement stock options exercisable for 3,000 shares of G1’s common stock and 1,500 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
Dermatology Devices Market Size, CAGR, Trends and Forecast 2024 to 2033
3/28/2024
According to Vision Research Reports, the global dermatology devices market size was estimated at USD 15.31 billion in 2023
-
Genetic Analysis Market Size to Attain Around USD 23.60 BN by 2033
3/28/2024
The global genetic analysis market was evaluated at USD 10.55 billion in 2023 and is expected to attain around USD 23.60 billion by 2033
-
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
3/28/2024
Biodexa Pharmaceuticals, an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment of Diffuse Midline Glioma in pediatric patients and for Recurrent Glioblastoma in adults; two aggressive brain cancers with universally poor prognoses.
-
Aptose Reports Results for the Fourth Quarter and Full Year 2023
3/26/2024
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and year ended December 31, 2023, and provided a corporate update.
-
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection
3/25/2024
Bluejay Therapeutics, Inc. Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to BJT-778 for the treatment of Chronic Hepatitis Delta Virus (HDV) infection.